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Abstract
Background Mesonephric adenocarcinoma of the vagina
is an extremely rare tumor of the female genital tract,
with only a few cases reported so far worldwide. Con-
sequently, there is no established standard treatment and
limited knowledge about the prognosis and biologic behav-
ior of vaginal mesonephric adenocarcinoma.
Methods This report documents a new case of vaginal
mesonephric adenocarcinoma diagnosed in a 54-year-old
woman, and analyzes this in the context of all previously
published cases.
Results MRI demonstrated that the 2.5 × 1.8 cm tumor of
the vaginal wall was invading urethra and bladder. Fol-
lowing surgical excision, histologic analysis determined
mesonephric adenocarcinoma of the vagina, stage pT2 R1.
In order to avoid the mutilating extended surgery which
would be required to reach R0 and considerable impairment
of quality of life, adjuvant radiochemotherapy was admin-
istered with external radiation and brachytherapy, including
5 cycles of cisplatin (40 mg/m²) for radiosensitization. Af-
ter 4 years of continuous oncologic follow-up, the patient
is alive and clinically free of disease.
Conclusion In this case it was shown that adjuvant ra-
diochemotherapy with radiation and brachytherapy was ef-
fective to manage the surgical R1 situation and maintain
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the patient’s life quality. More published cases reports are
needed to gradually substantiate optimal treatment strate-
gies.
Keywords Quality of life · Diethylstilbestrol ·
Brachytherapy · Radiochemotherapy · Radiotherapy
Das mesonephrische Adenokarzinom der Vagina
Diagnostik und multimodale Behandlung eines seltenen Tu-
mors und Analyse der weltweiten Erfahrung
Zusammenfassung
Hintergrund Das mesonephrische Adenokarzinom der Va-
gina ist ein äußerst seltener Tumor des weiblichen Genital-
trakts. In der internationalen Literatur finden sich nur wenig
gut dokumentierte Fälle. Das biologische Verhaltensmuster
dieses Tumors und dessen Prognose sind weitgehend unbe-
kannt.
Methoden In diesem Bericht wird ein neuer Fall einer 54-
jährigen Frau mit einem mesonephrischen Adenokarzinom
der Vagina vorgestellt und unter Berücksichtigung aller bis-
her publizierten Fälle analysiert.
Ergebnisse Bei dem 2,5 × 1,8 cm großen Tumor der Va-
ginalwand zeigte sich in der Magnetresonanztomographie
eine Infiltration der Urethra und Harnblase. Es wurde eine
Exzision des Tumors vorgenommen. Histologisch ergab
sich ein mesonephrisches Adenokarzinom der Vagina im
Stadium pT2 R1. Eine R0-Resektion wäre nur durch ein
aggressives chirurgisches Vorgehen möglich gewesen. Um
diese massive Einschränkung der Lebensqualität zu vermei-
den, wurde eine adjuvante Radiochemotherapie mit exter-
ner Bestrahlung und Brachytherapie mit 5 Zyklen Cisplatin
(40 mg/m²) zur Strahlensensibilisierung durchgeführt. Die
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Patientin ist im 4-Jahres-Follow-up beschwerdefrei und
ohne Rezidivgeschehen.
Schlussfolgerung In diesem Fall ist die adjuvante Radioche-
motherapie mit Brachytherapie die bestmögliche Strategie,
um auf die chirurgische R1-Situation einzugehen und dabei
die Lebensqualität der Patientin zu erhalten. Weitere Fall-
berichte sind nötigt, um optimale Behandlungsstrategien zu
etablieren.
Schlüsselwörter Lebensqualität · Diethylstilbestrol ·
Brachytherapie · Radiochemotherapie · Strahlentherapie
Background
Mesonephric adenocarcinoma (MA) of the vagina is a rare
tumor of the female genital tract, with only six cases listed
in MEDLINE as of March 2016 (Table 1). A few more
reports on MA occurring in the cervix, uterus, and urinary
bladder, including pediatric patients, have been published
[1–3, 6, 7, 14, 16].
The first link between adenocarcinoma of the vagina and
intrauterine exposure to diethylstilbestrol (DES) was de-
scribed in 1971 [11]. DES is an orally administered active
synthetic estrogen which was routinely given to selected
pregnant woman from about the 1940s to the 1960s, in the
mistaken belief it would reduce the risk of pregnancy com-
plications and losses. Follow-up studies demonstrated that
exposure to DES in utero causes a spectrum of congenital
anomalies in females, cervical and vaginal adenosis being
those most commonly found [13]. MAs exhibit a variety of
morphologic patterns and may therefore be confused with
mixed Müllerian tumors and other neoplasms. Immuno-
histochemical findings may help to distinguish MAs from
their Müllerian counterparts [2]. Many of the reported cases
were previously categorized as mesonephric carcinoma and
are now reclassified as clear-cell carcinoma of Müllerian
type.
We present the case report of a 54-year-old woman with
MA of the vaginal wall invading urethra and bladder and
describe the course of treatment.
Gynecologic case presentation
A 54-year-old Caucasian woman (1G 1P – 1 gravida, 0
para) was referred to the Obstetrics/Gynecology Depart-
ment because of vaginal bleeding after cohabitation. During
clinical examination, a tumor of size 2.5 × 1.8 cm located
underneath the urethra was visible. In pelvic MRI, invasion
of the urethra and the urinary bladder by the tumor was
described, without any evidence of suspect lymph nodes.
A cystoscopy showed no pathologic findings. Biopsy of the
tumor revealed vaginal adenosis with microglandular hyper-
plasia. However, the presence of an adenocarcinoma could
not be excluded. Local excision of the lesion was performed
in general anesthesia (ITN). Histopathologic workup con-
firmed infiltration of the urethra and of parts of the mus-
cularis of the urinary bladder. Microscopically, the tumor
showed a tubulocystic and papillary pattern, with scanty
pale to eosinophilic cytoplasm with low nuclear atypia.
The immunohistochemical profile of the tumor cells was
positive for pancytokeratin and CK7, but for calretinin and
vimentin only focal positive. Furthermore estrogen and pro-
gesterone receptor were negative and CD 10 was slightly
positive.
The final diagnosis was MA of the vagina, stage pT2 R1.
Achievement of an R0 resection would only have been pos-
sible by extended, mutilating surgery resulting in a severely
impaired quality of life. Hence, in the interdisciplinary tu-
mor board the consecutive decision was made to treat in
a conservative approach by adjuvant radiotherapy including
sensitization with cisplatin in analogy to treatment strate-
gies for gynecological adenocarcinoma [8].
Radiotherapy
The planning target volume comprised the vulva, vagina,
and the whole uterus, as well as bilateral inguinal, exter-
nal, and internal iliac lymph nodes up to the pelvic inlet as
the cranial field border. CT-based 3D-treatment planning
was performed in supine position. External beam radiother-
apy (EBRT) was delivered as intensity-modulated radiation
therapy (IMRT; step-and-shoot, daily image guidance) with
15-MV photons on a linear accelerator (Elekta Synergy;
Elekta, Stockholm, Sweden) [9], in single fractional doses
of 1.8 Gy (5 fractions/week) up to a total dose of 48.6 Gy.
EBRT was followed by fractionated high-dose rate (HDR)
brachytherapy delivered by a vaginal applicator. The entire
length of the vaginal mucosa including the whole introitus
was treated with an additional overall surface dose of 22 Gy
in two treatment courses in weekly distance, each of them
comprising three fractions of 3.5 Gy (bid) or 4 Gy (once
daily) on two consecutive days. Radiosensitization was per-
formed with concomitant chemotherapy consisting of five
cycles of cisplatin (40 mg/m²) once per week throughout
the EBRT course, up to an overall dose of 329 mg at an
individual body surface area of 1.67 m², according to com-
mon schedules for adjuvant treatment regimens in cervical
carcinoma and following the suggestions of a previous case
report [7]. The patient is alive and clinically free of disease
at 4 years of follow-up.
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8.7 years
NED 36 months 1 month n.k.
ResTu resection of the tumor, AWD alive with disease, BSO bilateral salpingo-oophorectomy, LFN lymphadenectomy, NED no evidence of
disease, TAH total abdominal hysterectomy, BT brachytherapy, VH vaginal hysterectomy, SCH supracervial hysterectomy, n.k. not known
Discussion
Mesonephric adenocarcinoma of the vagina is a rare en-
tity and any knowledge about is it therefore very limited.
Prognosis, biologic behavior, and treatment strategies are
controversially discussed and due to the rareness of the dis-
ease, there is no established standard therapy. Moreover,
the histopathologic findings are complex and immunohis-
tochemical studies show different results [5, 12]. Therefore,
many cases previously categorized as MA have been reclas-
sified as clear-cell carcinomas or malignant mixed Mülle-
rian tumors, and vice versa [17].
The Müllerian and Wolffian ducts originate from meso-
dermal tissue. These ducts develop in both male and female
embryos. In females the Müllerian ducts develop to form
the Fallopian tubes, uterus, cervix, and upper two-thirds of
the vagina; whereas in males they regress. Conversely, the
Wolffian ducts form the male internal genitals but atrophy
in females due to the absence of testosterone [10]. MAs
may arise out of these remnants [15].
Compared to the malignant mixed Müllerian tumor, it
seems that MAs located in the female genital tract have
a better prognosis [2].
However, the optimal management strategy for MA re-
mains uncertain. Treatment recommendations can evolve
only gradually, based on episodic reports and, in principle,
derived in analogy to allegedly comparable oncologic con-
stellations. Radical surgery is suggested as a potentially
curative option, particularly when malignant lesions appear
well capsulated [3]. In this patient, RO resection would
have only been possible by extended surgery with subse-
quent functional losses. Therefore, it was decided to treat
by radiochemotherapy in a multimodal approach, in anal-
ogy to therapeutic approaches for frequent gynecological
adenocarcinomas, e. g., vaginal cancer [4].
Conclusion
Despite a limited current follow-up time of 4 years, this
favorable disease course supports the hypothesis that these
rare tumors are sensitive to adjuvant chemoradiation. Adju-
vant treatment should be considered in cases with a higher
probability of microscopic remnants, thus potentially also
avoiding mutilation without compromising oncologic out-
come.
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